Makary Resigns as FDA Chief Amid Turmoil

Marty Makary has resigned from his position as Commissioner of the Food and Drug Administration (FDA), concluding a tumultuous 13-month tenure marked by controversy and internal strife. According to multiple sources, including The Guardian, Reuters, and CBS News, Makary's departure follows clashes with President Trump over the approval of flavored vapes and criticism from anti-abortion groups regarding his handling of mifepristone, an abortion pill.

Kyle Diamantas, the deputy commissioner for food, will serve as acting commissioner. As reported by The Guardian, Diamantas previously worked as a corporate lawyer defending Abbott Laboratories against claims that its infant formula increased the risk of a deadly gastrointestinal condition. He has no professional medical experience but is described as a non-controversial pick within the agency.

Makary's tenure was marked by significant turmoil, including the departure of several key allies and regulators. According to The Guardian, Tracy Beth Høeg, the acting drug chief, claimed she was fired after declining to resign. Katherine Szarama, the acting vaccines chief, also reportedly left the agency. The FDA now has no permanent commissioner or deputy commissioner and no permanent leaders of two major centers.

Makary's resignation comes amid a broader shake-up within the Department of Health and Human Services (HHS). As noted by Democracy Now!, HHS Secretary Robert F. Kennedy Jr. has been criticized for his handling of public health issues, including vaccines and the recent hantavirus outbreak on a cruise ship. The abrupt leadership changes at the FDA have raised concerns about the future of health and medicine in the United States.

The FDA's decision to withhold approval of a new skin cancer treatment also drew criticism from oncologists and pharmaceutical industry analysts, as reported by CBS News. Despite the benefit to some patients, there were legitimate concerns about the treatment that may have led to its rejection. The agency's decision-making process has been questioned, with critics arguing that it lacks transparency and consistency.

The FDA's leadership vacuum is expected to create uncertainty for the biotech sector. As noted by Reuters, analysts and investors believe that until a permanent replacement is found, the industry could face pressure. The departure of Makary and several key allies at the FDA signifies a potential new direction for the agency, which has been rocked by controversial decisions on vaccines, rare disease medications, staff layoffs, and low morale.